ATE377424T1 - Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion - Google Patents

Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion

Info

Publication number: ATE377424T1
Authority: AT; Austria
Prior art keywords: diabetes mellitus; cells; carbopol; silymarin; regeneration
Prior art date: 2002-12-13

Application number

AT03781099T

Other languages

English (en)

Inventor

Peredo Claudia Soto

Original Assignee

Univ Autonoma Metropolitana

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-13

Filing date

2003-12-11

Publication date

2007-11-15

2003-12-11 Application filed by Univ Autonoma Metropolitana filed Critical Univ Autonoma Metropolitana

2007-11-15 Application granted granted Critical

2007-11-15 Publication of ATE377424T1 publication Critical patent/ATE377424T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 3
SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 title abstract 2
229920002125 Sokalan® Polymers 0.000 title abstract 2
210000004923 pancreatic tissue Anatomy 0.000 title abstract 2
SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title abstract 2
229960004245 silymarin Drugs 0.000 title abstract 2
235000017700 silymarin Nutrition 0.000 title abstract 2
230000002124 endocrine Effects 0.000 title 1
230000008929 regeneration Effects 0.000 title 1
238000011069 regeneration method Methods 0.000 title 1
230000028327 secretion Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT03781099T 2002-12-13 2003-12-11 Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion ATE377424T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
MXPA02012315A MXPA02012315A (es)	2002-12-13	2002-12-13	Compuesto farmaceutico que contiene silimarina y carbopol, su proceso de fabricacion y su uso como regenerador del tejido y celulas pancreaticas de secrecion endogena danados por diabetes mellitus.

Publications (1)

Publication Number	Publication Date
ATE377424T1 true ATE377424T1 (de)	2007-11-15

Family

ID=32589024

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03781099T ATE377424T1 (de)	2002-12-13	2003-12-11	Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion

Country Status (8)

Country	Link
US (1)	US20060041009A1 (de)
EP (1)	EP1576961B1 (de)
AT (1)	ATE377424T1 (de)
AU (1)	AU2003288793A1 (de)
DE (1)	DE60317367T2 (de)
ES (1)	ES2295670T3 (de)
MX (1)	MXPA02012315A (de)
WO (1)	WO2004054600A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1327835C (zh) *	2004-07-08	2007-07-25	北京科信必成医药科技发展有限公司	水飞蓟素口腔崩解片及其制备方法
EP2291182A1 (de) *	2008-05-13	2011-03-09	Genmedica Therapeutics SL	Salicylat-konjugate zur behandlung von stoffwechselerkrankungen
CA2755069A1 (en) *	2009-03-16	2010-09-23	Genmedica Therapeutics Sl	Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (zh) *	2009-03-16	2012-04-18	根梅迪卡治疗公司	用于治疗代谢性疾病的组合疗法
US8466197B2 (en)	2010-12-14	2013-06-18	Genmedica Therapeutics Sl	Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
ES2861593B2 (es) *	2020-04-03	2023-05-22	Univ Valladolid	Composicion farmaceutica que comprende una disolucion de silimarina en un solvente eutectico profundo de origen natural, metodos de obtencion y uso en medicina

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4844883A (en) *	1987-01-20	1989-07-04	Florasynth, Inc.	Stabilization of wintergreen flavor in chalk-based dentifrice and method
JP3783999B2 (ja) *	2000-03-14	2006-06-07	アピ株式会社	プロポリス組成物
US6524599B2 (en) *	2001-02-21	2003-02-25	Skinceuticals, Inc.	Use of milk thistle extract in skin care compositions
AUPR510001A0 (en) *	2001-05-18	2001-06-14	Jupitar Pty Ltd	Formulation and method
EP1501520A1 (de) *	2002-05-06	2005-02-02	Diakron Pharmaceuticals, Inc.	Pharmazeutische zubereitung zur reduktion des glucose- und cholesterin-spiegels im blut

2002
- 2002-12-13 MX MXPA02012315A patent/MXPA02012315A/es active IP Right Grant
2003
- 2003-12-11 ES ES03781099T patent/ES2295670T3/es not_active Expired - Lifetime
- 2003-12-11 AT AT03781099T patent/ATE377424T1/de not_active IP Right Cessation
- 2003-12-11 DE DE60317367T patent/DE60317367T2/de not_active Expired - Lifetime
- 2003-12-11 US US10/538,277 patent/US20060041009A1/en not_active Abandoned
- 2003-12-11 AU AU2003288793A patent/AU2003288793A1/en not_active Abandoned
- 2003-12-11 EP EP03781099A patent/EP1576961B1/de not_active Expired - Lifetime
- 2003-12-11 WO PCT/MX2003/000108 patent/WO2004054600A1/es not_active Ceased

Also Published As

Publication number	Publication date
AU2003288793A1 (en)	2004-07-09
EP1576961B1 (de)	2007-11-07
ES2295670T3 (es)	2008-04-16
WO2004054600A1 (es)	2004-07-01
WO2004054600B1 (es)	2004-09-02
AU2003288793A8 (en)	2004-07-09
US20060041009A1 (en)	2006-02-23
DE60317367D1 (de)	2007-12-20
EP1576961A1 (de)	2005-09-21
MXPA02012315A (es)	2004-06-24
DE60317367T2 (de)	2008-09-25

Similar Documents

Publication	Publication Date	Title
Deacon	2004	Circulation and degradation of GIP and GLP-1
TR200100079T2 (tr)	2001-06-21	Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
ATE534404T1 (de)	2011-12-15	Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
ATE409466T1 (de)	2008-10-15	Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
CA2449540A1 (en)	2004-05-19	Method of treating left ventricular dysfunction
CA2252576A1 (en)	1997-11-06	Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals
AU3432295A (en)	1996-05-02	Glucagon-like insulinotropic peptide analogs compositions, and methods of use
ATE170401T1 (de)	1998-09-15	Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
ID30237A (id)	2001-11-15	KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
WO2006096829A3 (en)	2007-01-11	Thyrotropin-releasing hormone analogs and method of use
NO940180D0 (no)	1994-01-18	Anvendelse av IGF-I
TR199903142T2 (xx)	2000-09-21	Pankreas dokusu adac�� transplantasyonu i�in CD154 blokaj tedavisi.
WO2007084544A3 (en)	2008-02-07	Methods of treating or preventing tissue damage caused by increased blood flow
ATE377424T1 (de)	2007-11-15	Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion
IL146868A0 (en)	2002-08-14	A pharmaceutical composition containing an igf-i/igfbp-3 complex
ATE310957T1 (de)	2005-12-15	Vorhersagen ueber von diabetes beeintraechtigte wundheilung
HK1042852A1 (zh)	2002-08-30	增强胰岛素反应的方法
Singh	2015	Glucagon-like peptide 1 and dysglycemia: conflict in incretin science
An et al.	2013	Improved glycemic control enhances the incretin effect in patients with type 2 diabetes
WO2005070444A8 (en)	2006-08-03	Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
TW200716159A (en)	2007-05-01	Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
ATE439854T1 (de)	2009-09-15	Proteinhydrolysat mit antidiabetischer wirkung
Crunkhorn	2021	Illuminating the incretin effect
Meier et al.	2022	Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment
Schubert	2000	Gastric secretion

Legal Events

Date	Code	Title	Description
2008-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties